Skip to main content
. Author manuscript; available in PMC: 2009 Jun 4.
Published in final edited form as: Technol Cancer Res Treat. 2009 Jun;8(3):187–200. doi: 10.1177/153303460900800303

Figure 4.

Figure 4

Biological dose analyses in esophagus for the 4D composite plans, P0% IMRT plans, and P50% IMRT plans of the nine lung cancer patients. Comparisons of (a) normal tissue complication probability and (b) biologically effective uniform dose (D¯¯) with (c) mean dose in esophagus were illustrated.